Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2025Current Medical Research and Opinion

Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAleksandrina RusevaNovo Nordisk (United States)AFAnthony N. FabricatoreNovo Nordisk (United States)BHBríain ó HartaighNovo Nordisk (United States)

Discussion

Loading...

Member takes

Overview

Cohort study demonstrates weight reduction with semaglutide in patients with obesity and overweight, suggesting effectiveness in chronic weight management.

Key Points

  • Weight reduction and improved BMI observed at 24 months with semaglutide in patients with obesity or overweight.
  • Cohort study assessed real-world outcomes, reflecting practical implications for weight management.
  • Semaglutide may lead to better cardiometabolic risk factors, highlighting potential health benefits for patients.
  • Results support semaglutide's role as an effective treatment option in clinical practice for chronic weight management.

Cite This Study

Ruseva et al. (2025) studied this question.

synapsesocial.com/papers/694020fd2d562116f28fb59chttps://doi.org/10.1080/03007995.2025.2591464
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months)2025 · 13 citations
  2. 2A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss2024 · 16 citations
  3. 3Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study2025 · 7 citations
  4. 41691-P: Clinical Outcomes in Patients with Obesity or Overweight Treated with Semaglutide 2.4 mg—A Real-World Retrospective Cohort Study in the United States (SCOPE 2)2024
  5. 5Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system2026